Noracymethadol (INN) is a synthetic opioid analgesic related to methadone that was never marketed.

[2] In a clinical trial of postpartum patients it was reported to produce analgesia comparable to that of morphine but with less nausea, dizziness, and drowsiness.

[3][4] Other side effects included salivation, ataxia, and respiratory depression that was reversible by naloxone.

[3][4] Similarly to many of its analogues, noracymethadol is a Schedule I controlled substance in the United States with an ACSCN of 9633 and 2013 annual manufacturing quota of 12 grammes.

[5] and is also controlled internationally under the United Nations Single Convention on Narcotic Drugs of 1961.